A detailed history of Wynnefield Capital Inc transactions in Landec Corp \Ca\ stock. As of the latest transaction made, Wynnefield Capital Inc holds 4,918,979 shares of LNDC stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,918,979
Previous 4,923,545 0.09%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
N/A
-4,566 Reduced 0.09%
4,918,979 $0
Q1 2023

May 15, 2023

BUY
N/A
461,035 Added 10.33%
4,923,545 $0
Q4 2022

Feb 14, 2023

BUY
$0.0 - $9.95 $0 - $9.25 Million
929,223 Added 26.3%
4,462,510 $0
Q1 2022

May 16, 2022

BUY
$10.07 - $11.93 $3.9 Million - $4.62 Million
387,400 Added 12.31%
3,533,287 $40.9 Million
Q2 2021

Aug 16, 2021

BUY
$9.91 - $12.78 $2.38 Million - $3.07 Million
240,587 Added 8.28%
3,145,887 $35.4 Million
Q1 2021

May 17, 2021

BUY
$10.44 - $12.22 $208,800 - $244,400
20,000 Added 0.69%
2,905,300 $30.7 Million
Q4 2020

Feb 16, 2021

BUY
$9.3 - $11.77 $93,000 - $117,700
10,000 Added 0.35%
2,885,300 $31.3 Million
Q2 2020

Aug 14, 2020

BUY
$7.96 - $11.54 $39,800 - $57,699
5,000 Added 0.17%
2,875,300 $22.9 Million
Q3 2019

Nov 14, 2019

BUY
$9.66 - $12.36 $724,500 - $927,000
75,000 Added 2.68%
2,870,300 $31.2 Million
Q2 2019

Aug 14, 2019

BUY
$9.32 - $12.98 $559,200 - $778,800
60,000 Added 2.19%
2,795,300 $26.2 Million
Q1 2019

May 15, 2019

BUY
$10.35 - $13.06 $547,515 - $690,874
52,900 Added 1.97%
2,735,300 $33.6 Million
Q3 2017

Nov 14, 2017

BUY
$11.95 - $13.35 $32.1 Million - $35.8 Million
2,682,400
2,682,400 $34.7 Million

Others Institutions Holding LNDC

About LANDEC CORP \CA\


  • Ticker LNDC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 29,595,600
  • Description
  • Landec Corporation operates as a diversified health and wellness company. The company manufactures pharmaceutical-grade sodium hyaluronate (HA)-based biomaterials for primary use in the ophthalmic and orthopedic markets. It also provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated, a...
More about LNDC
Track This Portfolio

Track Wynnefield Capital Inc Portfolio

Follow Wynnefield Capital Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wynnefield Capital Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wynnefield Capital Inc with notifications on news.